BioWorld MedTech

Dec. 8, 2016

Abbott ready to bolt on Alere based on 'damaging business developments'

After nearly 10 months of waffling on a $5.8 billion decision, Abbott Laboratories might have spotted an emergency exit from its contract to buy Alere Inc. Read More

MIT team reduces beta amyloid plaques in mice using light therapy

Cures Act sails through Senate in 94-5 landslide

AdvaMed's Trunzo says least burdensome standard revived

EU sliding toward a compliance cliff as regulations advance

Attorney says outcome of hearing on CRISPR patents tough to predict

Abiomed Impella CP gets green light for high-risk PCI treatment

Appointments and advancements

Product briefs

Financings

Other news to note

MDD's Orthopedics Extra

Today's news in brief

BioWorld

BioWorld briefs for June 16, 2026.

News in brief

BioWorld Asia

BioWorld Asia briefs for June 16, 2026

EHA 2026: With new lenses, a changing view on pediatric cancers

BioWorld

In the most simplistic view, adult cancers occur because “immature cells are exposed to mutagens, accumulate mutations, and across life ultimately transform into...

Medical illustration showing layers of a blood vessel

Anti-C5aR1 antibodies linked to outcomes in giant cell arteritis

BioWorld Science

More effective glucocorticoid-sparing therapies are needed for the treatment of giant cell arteritis (GCA). Studies found that complement signaling pathways...

Fortvita and Innovent patent new anti-TROP2/B7-H4 ADCs

BioWorld Science

Fortvita Biologics Inc. and Innovent Biologics (Suzhou) Co. Ltd. have jointly reported new antibody-drug conjugates (ADCs) comprising a bispecific antibody or...